For example, the upregulated expression of PDIA1 (also known as PDI) and PDIA3 (ERp57) have been reported in the cancers of brain, lymphoma, kidney, ovarian, prostate, lung, and colon and have been considered as diagnostic biomarkers and therapeutic targets for cancer treatment and chemoprevention (17, 18). Here, PDIA2 is linked to cancer.